Q
QuantAbundanceAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

29,778 signal articles · 38 in last 24h · 148,416 total before filter · latest 4h ago
38last 24h
969last 7d
108● bullish (7d)
121● bearish (7d)
212publishers
AllMacro369Earnings113M&A98Regulatory8Product11Analyst9
✕ clear all filtersticker: NOVTsentiment: neutralSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Is Novanta’s (NOVT) High-Margin Revenue Momentum Redefining Its Competitive Moat?
Simply Wall St.6h agoneutral
Is Novanta’s (NOVT) High-Margin Revenue Momentum Redefining Its Competitive Moat?

In recent commentary, Novanta (NASDAQ:NOVT) has been highlighted for its multi-year annual revenue growth of 10.7% and a gross margin of 44.4%, reflecting perceived market share gains and strong product positioning. This attention centers on Novanta’s combination of demand acceleration expectations and high-margin products, which analysts view as evidence of superior competitive capabilities. Next, we will examine how this focus on Novanta’s revenue momentum and margins may influence the...

1 High-Flying Stock Worth Your Attention and 2 We Ignore
StockStory1d agoneutral
1 High-Flying Stock Worth Your Attention and 2 We Ignore

“You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated volatility during market downturns when expectations change.

Novanta’s (NOVT) Second Quarter Shows Profits Outrunning Sales
Insider Monkey15d agoneutral
Novanta’s (NOVT) Second Quarter Shows Profits Outrunning Sales

On August 5, Novanta Inc. (NASDAQ:NOVT) reported second quarter results showing something rarer than strong revenue growth: profit growth that beat it by a wide margin. Revenue rose 10.3% year over year to $265.8 million, but net income nearly tripled and cash from operations quadrupled. That kind of gap between the top and bottom line […]

1 Small-Cap Stock with Promising Prospects and 2 We Brush Off
StockStory33d agoneutral
1 Small-Cap Stock with Promising Prospects and 2 We Brush Off

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.

5 Revealing Analyst Questions From Novanta’s Q2 Earnings Call
StockStory36d agoneutral
5 Revealing Analyst Questions From Novanta’s Q2 Earnings Call

Novanta's second quarter was marked by broad-based organic growth across all business units and a favorable response from the market. Management attributed the strong results to both an acceleration in new product revenue—up more than 50% year-over-year—and operational improvements, including factory consolidations. CEO Matthijs Glastra highlighted that all business units grew organically and pointed to increased customer demand in precision robotics, AI-driven manufacturing, and minimally invas

NOVT Q2 Deep Dive: Acquisition and Manufacturing Moves Drive Outlook Higher
StockStory40d agoneutral
NOVT Q2 Deep Dive: Acquisition and Manufacturing Moves Drive Outlook Higher

Medicine and manufacturing technology provider Novanta (NASDAQ:NOVT) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 10.3% year on year to $265.8 million. On top of that, next quarter’s revenue guidance ($302 million at the midpoint) was surprisingly good and 14.9% above what analysts were expecting. Its non-GAAP profit of $0.89 per share was 7.2% above analysts’ consensus estimates.

Novanta (NOVT) Lifted Guidance And Closed Riverpoint, Is The Upside Already Priced In?
Simply Wall St.41d agoneutral
Novanta (NOVT) Lifted Guidance And Closed Riverpoint, Is The Upside Already Priced In?

What Novanta’s latest guidance and Q2 results mean for the stock Novanta (NOVT) put fresh numbers on the table on 5 August 2026, pairing new third quarter and full year revenue guidance with second quarter results and the recently closed Riverpoint Medical acquisition. The company now guides third quarter 2026 GAAP revenue to US$300 million to US$304 million, with the range reflecting an expected contribution from Riverpoint Medical and an assumption of steady foreign exchange rates. For full...

Novanta (NOVT) Closes Its Largest Acquisition】【。
Simply Wall St.41d agoneutral
Novanta (NOVT) Closes Its Largest Acquisition】【。

Novanta (NasdaqGS:NOVT) has closed its acquisition of RiverPoint Medical, the largest deal in the company's history. The transaction expands Novanta's exposure to medical end markets and is expected to be immediately accretive to revenue growth and margins. Management is accelerating a manufacturing restructuring plan alongside the RiverPoint integration, with potential long-term effects on efficiency and profitability. For investors watching how medical technology companies scale up and...

Novanta Q2 Earnings Call Highlights
MarketBeat43d agoneutral
Novanta Q2 Earnings Call Highlights

Novanta (NASDAQ:NOVT) reported second-quarter results marked by 9% organic sales growth, expanding margins and higher operating cash flow, while raising its full-year outlook following the late-July closing of its Riverpoint Medical acquisition. Chair and Chief Executive Officer Matthijs Glastra sa

Increased Bookings Reinforce Novanta’s (NOVT) Broadening Organic Momentum
Insider Monkey44d agoneutral
Increased Bookings Reinforce Novanta’s (NOVT) Broadening Organic Momentum

Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 and the Russell 2000 Growth Index up 25.7% in Q2, fueled by AI enthusiasm […]

Novanta’s (NASDAQ:NOVT) Q2 CY2026 Sales Top Estimates, Guides for Strong Full-Year Sales
StockStory45d agoneutral
Novanta’s (NASDAQ:NOVT) Q2 CY2026 Sales Top Estimates, Guides for Strong Full-Year Sales

Medicine and manufacturing technology provider Novanta (NASDAQ:NOVT) announced better-than-expected revenue in Q2 CY2026, with sales up 10.3% year on year to $265.8 million. On top of that, next quarter’s revenue guidance ($302 million at the midpoint) was surprisingly good and 14.9% above what analysts were expecting. Its non-GAAP profit of $0.89 per share was 7.2% above analysts’ consensus estimates.

2 High-Flying Stocks Worth Investigating and 1 We Avoid
StockStory79d agoneutral
2 High-Flying Stocks Worth Investigating and 1 We Avoid

Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expectations are already baked into their prices, leaving little room for error if they stumble even slightly.

Broader Market Settles Lower as Chip Stocks Sink
Barchart102d agoneutral
Broader Market Settles Lower as Chip Stocks Sink

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -0.26%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.17%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.12%. June E-mini S&P futures (ESM26 ) fell -0.36%, and June E-mini Nasdaq futures...

Stocks Climb on an AI-Led Rebound
Barchart102d agoneutral
Stocks Climb on an AI-Led Rebound

The S&P 500 Index ($SPX ) (SPY ) today is up +0.93%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.89%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.17%. June E-mini S&P futures (ESM26 ) are up +0.76%, and June E-mini Nasdaq futures...

3 Small-Cap Stocks We Think Twice About
StockStory103d agoneutral
3 Small-Cap Stocks We Think Twice About

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.

Assessing Novanta (NOVT) Valuation After A Sharp Short Term Share Price Run
Simply Wall St.110d agoneutral
Assessing Novanta (NOVT) Valuation After A Sharp Short Term Share Price Run

Understanding Novanta after its recent share move Novanta (NOVT) has drawn investor attention after a recent share price move, prompting a closer look at how the company’s current fundamentals line up with its recent market performance. See our latest analysis for Novanta. Novanta’s recent share price move comes after a strong run, with a 30 day share price return of 24.6% and a year to date share price return of 43.36%. The 1 year total shareholder return is 28.68%, but the 3 year total...

3 Cash-Heavy Stocks We Approach with Caution
StockStory117d agoneutral
3 Cash-Heavy Stocks We Approach with Caution

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.